- ►annals.org [PDF] J Rosenstock, B Zinman, LJ Murphy, SC … - Annals of internal medicine, 2005 - Am Coll Physicians Inhaled Insulin Improves Glycemic Control When Substituted for or ... Added to
Oral Combination Therapy in Type 2 Diabetes ... Julio Rosenstock, MD; Bernard
Zinman, MD; Liam J. Murphy, MD; Stephen C. Clement, MD; Paul Moore, MD; C. ... Cited by 163 - Related articles - BL Direct - All 8 versions
- ►colfar.com [PDF] - Free from Publisher PA Hollander, L Blonde, R Rowe, AE Mehta, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS— HbA 1c decreased similarly in the inhaled (−0.7%) and subcutaneous
(−0.6%) insulin groups (adjusted treatment group difference: −0.07%, 95% CI
−0.32 to 0.17). HbA 1c <7.0% was achieved in more patients receiving ... Cited by 237 - Related articles - BL Direct - All 21 versions
- ►diabetesjournals.org N Freemantle, L Blonde, D Duhot, M Hompesch … - Diabetes Care, 2005 - Am Diabetes Assoc Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment
of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin
formulation is delivered by aerosol, permitting the noninvasive ... Cited by 102 - Related articles - All 7 versions
- ►diabetesjournals.org J Rosenstock, JC Cappelleri, B Bolinder, RA … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of the 60 patients who received inhaled insulin during the parent
studies, 85.0% (n = 51) chose to continue treatment, 13.3% (n = 8) switched to
subcutaneous insulin, and 1.7% (n = 1) did not continue. Of the 61 patients ... Cited by 132 - Related articles - BL Direct - All 12 versions
- ►endojournals.org SE Fineberg, T Kawabata, D Finco-Kent, C Liu … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Research Design and Methods: Insulin antibody data from initial phase II/III
trials were analyzed comparing the efficacy and safety of inhaled insulin with
various agents, including sc insulin. Additionally, data from a 24-month ... Cited by 119 - Related articles - All 6 versions
- Free from Publisher RA DeFronzo, RM Bergenstal, WT Cefalu, J … - Diabetes Care, 2005 - cat.inist.fr OBJECTIVE- Effective type 2 diabetes management requires prompt intervention if
glycemic control is not achieved by nonpharmacological means. This study
investigates whether inhaled insulin(INH; Exubera) can achieve target ... Cited by 73 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org K Rave, S Bott, L Heinemann, S Sha, RHA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—INH had a faster onset of action than both RHI and ILP, as indicated
by shorter time to early half-maximal effect (32 vs. 48 and 41 min,
respectively; P < 0.001 for IHN vs. RHI and P < 0.05 for IHN vs. ILP). Time ... Cited by 112 - Related articles - All 7 versions
- ►ucalgary.ca [PDF] - Free from Publisher JS Skyler, RS Weinstock, P Raskin, JF Yale, E … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Mean glycosylated hemoglobin (A1C) decreased comparably from baseline
in the inhaled and subcutaneous insulin groups (−0.3 and −0.1%,
respectively; adjusted difference −0.16% [CI −0.34 to 0.01]), with a ... Cited by 104 - Related articles - BL Direct - All 10 versions
- Free from Publisher T Heise, S Bott, C Tusek, JA Stephan, T … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—For the INH and SC groups, mean (±SD) IAB levels were 3.5 ± 3.9 and
2.6 ± 4.1 μU/ml at baseline, respectively, compared with 101.4 ± 140.4 and
4.3 ± 9.4 μU/ml at week 24. At week 24, the changes from baseline were ... Cited by 80 - Related articles - BL Direct - All 6 versions
- Free from Publisher AH Barnett, M Dreyer, P Lange, M Serdarevic … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—In the A1C >9.5% arm, INH demonstrated a significantly greater
reduction in A1C than metformin. Mean adjusted changes from baseline were
−2.17 and −1.79%, respectively; between-treatment difference was ... Cited by 47 - Related articles - BL Direct - All 7 versions
